- Home
- PCM vs ONCY Comparison
PCM vs ONCY Comparison
Compare PCM & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCM
- ONCY
- Stock Information
- Founded
- PCM 1993
- ONCY 1998
- Country
- PCM United States
- ONCY Canada
- Employees
- PCM N/A
- ONCY N/A
- Industry
- PCM Trusts Except Educational Religious and Charitable
- ONCY Pharmaceuticals and Biotechnology
- Sector
- PCM Finance
- ONCY Health Care
- Exchange
- PCM Nasdaq
- ONCY Nasdaq
- Market Cap
- PCM 82.0M
- ONCY 89.7M
- IPO Year
- PCM N/A
- ONCY 1999
- Fundamental
- Price
- PCM $6.33
- ONCY $1.20
- Analyst Decision
- PCM
- ONCY Strong Buy
- Analyst Count
- PCM 0
- ONCY 5
- Target Price
- PCM N/A
- ONCY $5.00
- AVG Volume (30 Days)
- PCM 29.1K
- ONCY 885.1K
- Earning Date
- PCM 01-01-0001
- ONCY 11-07-2025
- Dividend Yield
- PCM 11.68%
- ONCY N/A
- EPS Growth
- PCM N/A
- ONCY N/A
- EPS
- PCM N/A
- ONCY N/A
- Revenue
- PCM N/A
- ONCY N/A
- Revenue This Year
- PCM N/A
- ONCY N/A
- Revenue Next Year
- PCM N/A
- ONCY N/A
- P/E Ratio
- PCM N/A
- ONCY N/A
- Revenue Growth
- PCM N/A
- ONCY N/A
- 52 Week Low
- PCM $6.88
- ONCY $0.33
- 52 Week High
- PCM $10.20
- ONCY $1.51
- Technical
- Relative Strength Index (RSI)
- PCM 33.26
- ONCY 49.73
- Support Level
- PCM $6.28
- ONCY $1.16
- Resistance Level
- PCM $6.41
- ONCY $1.32
- Average True Range (ATR)
- PCM 0.14
- ONCY 0.07
- MACD
- PCM -0.04
- ONCY -0.00
- Stochastic Oscillator
- PCM 22.10
- ONCY 53.33
About PCM PCM Fund Inc.
Pcm Fund Inc is a closed-end investment management company. Its investment objective is to seek current income as a primary focus and also capital appreciation. The Fund invests in agency-guaranteed mortgage-backed securities, private-label mortgage-backed securities, high-yield corporate debt securities, and commercial mortgage-backed securities.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.